Tesamorelin has an FDA-approved HIV lipodystrophy indication, but not for longevity, ordinary weight loss, cognition, bodybuilding, or anti-aging.
A buyer guide to UFC GYM's PWR Clinics announcement, gym-based longevity medicine, and what to verify before buying GLP-1, TRT, peptide, IV, or recovery programs.
A buyer guide to longevity medicine implementation: how to judge clinic delivery, governance, AI claims, incidental findings, and follow-up before you pay.
Neko lists its UK scan at £299 and plans to open in New York on September 24, 2026, but no US price is public. Here is what the scan includes and what to verify.
A buyer guide to Human Longevity exam cost, HLI-style diagnostics, genetics, full-body imaging, and the follow-up questions to ask before paying.
A practical guide to the follow-up plan after a longevity assessment: clinical ownership, abnormal findings, referrals, retesting, records, costs, and red flags.
A buyer scorecard for separating completed tests, biomarker changes, functional progress, patient-important outcomes, safety, and unresolved follow-up.
Retatrutide is promising in obesity trials, but products sold as retatrutide outside trials have triggered liver-toxicity warnings. Here is how clinic buyers can separate legitimate care from grey-market peptide risk.
A decision framework for choosing executive health, concierge prevention, or a longevity clinic in 2026 based on risk profile, diagnostics, follow-up, budget, and red flags.
A cautious 2026 guide to cognitive decline, longevity clinics, brain-health tests, lifestyle evidence, referral pathways, and red flags.
GLP-1 microdosing longevity clinics in 2026 need scrutiny: see evidence, healthy-lean caveats, product-quality risks, and buyer red flags.
IV nutrient therapy can be clinically useful for selected deficiencies, but anti-aging claims are weaker. Here is how to compare clinics, costs, and safety protocols.
VO2 max is one of the better-supported longevity metrics, but the value depends on testing quality, medical screening, and a plan after the number.
Lepodisiran and muvalaplin lower Lp(a) in phase 2, but cardiovascular outcomes are not yet proven. Here is the current phase 3 status and the clinic workflow that matters now.
This weekly WLC intelligence digest covers serious clinic standards, AI diagnostics, GLP-1 programs, full-body MRI, biological-age testing, and peptides.
A buyer guide to longevity clinic data systems: wearables, dashboards, clinical records, AI, interoperability, privacy, escalation, and proof to request.
A dated May 2026 evidence check on five longevity-clinic trends: AI diagnostics, GLP-1s, biomarkers, imaging, and changing care models.
A clear 2026 guide to what longevity clinics do, what they cost, which tests matter, red flags to avoid, and how to compare clinics safely.
A conflict-disclosed comparison of three Spanish longevity-clinic models using current provider pages, public price signals, clinical scope, evidence limits and booking questions.
A buyer's guide to full-body MRI at longevity clinics: what it can detect, what it misses, real cost models, false positives, and safer alternatives.
A provider-neutral 100-point scorecard for evaluating licensing, evidence, diagnostics, follow-up, pricing and records before paying a longevity clinic.
The viral post verifies a clinic visit, not a protocol, price, result, or recommendation. This fact check separates the reported event from the medical claims added around it.
A 2025 Aging editorial offers a useful agenda for longevity clinics, but it is a three-page, one-author opinion with one reference, not an evidence review or consensus statement.
A destination longevity program is still health care abroad. Use this CDC-based checklist to assess the clinic, clinician, procedure, travel risks, records, insurance, and follow-up before paying.
A current provider map shows three different Southern California models: scan-focused imaging, primary and concierge care, and integrated genomic assessment. They should not be compared as one product.
Longevity Clinics World can help build a shortlist, but a directory listing is not accreditation. Use these checks for credentials, evidence, total cost, follow-up, and conflicts.
US longevity clinics are not outside regulation, but oversight is split. This map explains FDA product rules, state professional oversight, compounding, off-label care, and what patients can verify.
ArentFox Schiff's longevity practice announcement is a useful prompt for an operator checklist covering licensing, claims, products, data, contracts, and cross-border care.
LifeWellMD advertises TRT, exosomes, peptides, infusions, and biological-age protocols. This claim audit shows what its own site establishes and what FDA or clinical guidance requires.
